1 **Original Article** 2 Are high urea values before intravenous immunoglobulin replacement a risk factor for 3 COVID-related mortality? 4 **Running Title**: Risk factors for COVID-related mortality? 5 6 Gökhan AYTEKİN^{1,*}, Emel ATAYIK¹ 7 8 9 ¹Department of Immunology and Allergy, Konya City Hospital, Konya, Turkey 10 *Correspondence: ayteking@gmail.com 11 12 ORCIDs: 13 Gökhan AYTEKİN: https://orcid.org/0000-0002-9089-5914 14 15 Emel ATAYIK: https://orcid.org/0000-0002-7011-7752 16 17 **Corresponding Author:** 18 Gokhan AYTEKIN, MD, 19 University of Health Sciences, Konya City Hospital, 20 Division of Allergy and Clinical Immunology, 21 42080, Konya Turkey **Phone:** +90 505 533 73 55 **Email:** ayteking@gmail.com 22 23 24 25 26

Informed consent The study protocol was approved by the Ethics committee of the Karatay University (with the decision dated 09.02.2021, decision number: 2020/021). Informed consent was obtained from study participants. Manuscripts that have not been presented orally or as a poster. **Funding source:** No funding was secured for the study. Financial disclosure: The authors have no financial relationship relevant to this article to disclose. **Conflict of interest:** The authors have no conflicts of interest to disclose. **Acknowledgement**: None **Disclaimers**: None **Abstract word count: 250 Text word count:** 3097

ORIGINAL ARTICLE

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

Title of the manuscript: Are high urea values before intravenous immunoglobulin replacement a risk factor for COVID-related mortality? **Abstract Objective:** Since the World Health Organization accepted The Coronavirus Disease 2019 (COVID-19) as a pandemic and there is still no effective treatment, it becomes crucial that the physicians interested in COVID-19 treatment share all the data they acquire, particularly in vulnerable patient groups, to reduce morbidity and mortality. Methods: The study included 81 adult (Female: 27, Male: 54) COVID-19 patients who were hospitalized for the treatment of COVID-19 between April 2020 and September 2020 and were followed-up, treated and consulted in the immunology clinic for intravenous immunoglobulin (IVIG) treatment. **Results:** The univariate analysis found that the number of days of hospitalization in service, being intubated, number of IVIG treatment days, and the urea value before IVIG treatment were independent risk factors for mortality (p:0.043, p:0.001, p:0.074, p:0.004, respectively). As a result of multivariate analysis, being intubated and urea value before IVIG treatment were found to be independent risk factors for mortality (p:0.001 and p:0.009). It was found that for 60 mg/dL level of urea value before IVIG treatment, the sensitivity value for mortality in COVID-19 patients was 46.2%, and the specificity was 35.5% (p:0.029)**Conclusion:** The study found that urea values before IVIG treatment were a risk factor for mortality in patients who received IVIG treatment for COVID-19. This is important as it indicates that BUN values should be closely monitored in patients given IVIG

- 74 treatment for COVID-19. It also suggests that when resources are limited and risk
- stratification is required in COVID-19 patients, BUN values can be helpful.
- 76 **Keywords:** SARS-CoV-2, immunoglobulin, mortality, blood urea nitrogen, COVID-19
- 77 -

1. Introduction

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (Sars-CoV-2), has affected the whole world in economic, social, spiritual, and many other areas, particularly in the field of health, since December 2019, when it was first described (1, 2). As the disease is highly contagious, the virus spread worldwide in a short time and caused one of the most catastrophic pandemics in human history (3). Although there are some vaccines to reduce virus transmission and develop protection against it, it is obvious that vaccinating all the people in the world will not be possible in such short term. Although it has been more than one year since the WHO (World Health Organization) accepted COVID-19 as a pandemic, there is still no effective treatment. Until now, many treatment options, particularly antimalarial drugs and antivirals, systemic corticosteroids, tocilizumab, anakinra, conventional plasma therapy, and intravenous immunoglobulin (IVIG) therapy, have been tried in the form of monotherapy or combinations for treating COVID-19, there is still no consensus on its treatment (4-7). For this reason, it becomes crucial that the physicians interested in COVID-19 treatment share all the data they acquire, particularly in vulnerable patient groups, to reduce morbidity and mortality. Regarding COVID-19 treatment management, many countries have created their treatment protocols, and many associations have published guidelines for its treatment. COVID-19 treatment in Turkey has been primarily applied in line with the TC Ministry of Health protocols. In general, the patients positive for SARS-CoV-2 Polymerase Chain Reaction (PCR) (+) were put on hydroxychloroguine and favipiravir treatment at appropriate doses. Patients who did not benefit from these treatments and/or had underlying risk factors were hospitalized. In addition to respiratory support treatments, patients were treated with conventional plasma, systemic steroid therapy, immunomodulatory therapies such as tocilizumab and anakinra, and IVIG treatment, whichever appropriate, as line therapies (8). IVIG was administered as per the clinical immunologists' opinions and in the proper dose and time intervals. Considering that pulmonary lesions in COVID-19 are caused by viral infiltrates and inflammatory response, IVIG treatment provides inflammatory cytokine balance, inhibits auto-reactive T cells, reduces antibody production from CD19⁺ B cells, and reduces macrophage activity. The IVIG treatment is thought to provide a regression in pulmonary lesions, reducing the need for mechanical ventilation, length of hospital stay, and mortality rates in these patients (9, 10). Therefore, this study aimed to retrospectively examine the data of patients who reported to the immunology clinic for IVIG treatment in a tertiary referral hospital and who were hospitalized, followed up, and treated for COVID-19. The study also investigated the effects of the patients' clinical, laboratory, and treatment characteristics and risk factors for mortality in patients with COVID-19 treating with IVIG treatment.

2. Methods

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

Study design and study population

The study included 81 adult (Female [F]: 27, 33.3%; Male [M]: 54, 66.7%) COVID-19 patients who were hospitalized for the treatment of COVID-19 in a tertiary referral hospital between April 2020 and September 2020 and were followed-up, treated and consulted in the immunology clinic for IVIG treatment. A review of medical records (including information on age, sex, disease duration) was undertaken. Venous blood samples for biochemical analyses were drawn after at least ten hours of fasting, early in

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

the morning. All biochemical analyses were conducted in the Central Biochemistry Laboratory of the Konya Education and Research Hospital. Complete blood counts were performed using Sysmex XN-10 (Sysmex Corporation, Kobe, Japan) analyzers with the fluorescent flow cytometry method. Serum creatinine levels were measured using the Jaffe method. Quantitative determination of serum IgG, IgM, IgA, and IgE was done through particle-enhanced immunonephelometry using the Siemens BN II/BN ProSpec system (Erlangen, Germany). The follow-up period of all patients started with their hospitalization. For the patients who died, the number of days between the date of hospitalization and death was accepted as the follow-up period. The duration of follow-up was calculated by confirming whether the discharged patients were alive or not through the TC Death Reporting System 2 weeks after discharge. For patients who died within two weeks of discharge, the follow-up period was accepted as the number of days between the date of hospitalization and death. For patients who lived more than two weeks after discharge, the follow-up period was calculated by adding 14 days to the number of days they stayed in the hospital. The time until hospitalization, resulting from the emergence of SARS-CoV-2-related symptoms such as fever, cough, and body pain, was considered the duration of illness. The duration of the follow-up in the service was specified as the day of hospitalization and the follow-up period in the intensive care unit as the duration of intensive care hospitalization. All patients in the study received IVIG treatment. Some patients were followed only in the service and received IVIG treatment in the service. Some patients received IVIG treatment in the intensive care unit. Patients who received IVIG

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

treatment in the service and those who received IVIG treatment in the first 24/48 h after their admission to intensive care were specified as the IVIG treatment ICU first 24/48 h. The systemic inflammatory index (SII) was calculated by the formula platelet x neutrophil/lymphocyte. The SARS-CoV-2 diagnosis was established with the detection of the SARS-CoV-2 genome via the PCR method from the nasopharyngeal sample (nasal swab) in patients with symptoms suggestive of SARS-CoV-2 infection such as fever, cough, shortness of breath, joint and body pain, and/or viral infiltration on lung imaging (PA chest radiography or lung tomography). The permission for the study was obtained from the Republic of Turkey, Ministry of Health Scientific Research Platform. In addition, an ethics committee approval was obtained from Karatay University Ethics Committee (with the decision dated 09.02.2021, decision number: 2020/021). Written informed consent was obtained from each patient. The study was conducted as per the principles of the Declaration of Helsinki. **Statistical Analyses** Statistical analyses were performed using the SPSS version 22.0 software package (IBM Corp., Armonk, NY, USA). Normally distributed parameters were presented as mean ±standard deviation, and data that were not normally distributed were expressed as median (interquartile range: minimum-maximum). Descriptive data were presented as frequencies and percentages and compared using the Chi-square test. Comparisons between baseline characteristics were performed by independent Student t, Mann-Whitney rank-sum, Fisher's exact or Chi-square tests where appropriate. Independent predictors for mortality were determined using binomial logistic regression analysis, Cox regression analysis, and Kaplan-Meier test. ROC curves are used to choose the most appropriate cut-off for urea level. A p-value of <0.05 was considered statistically significant.

3. Results

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

A total of 81 patients, 27 of whom were women (33.3%), were included in the study. The average age of the patients was 71 (26–94) years. During the follow-up, the mortality rate was 64.2%. The rate of intubated patients was 45.7%. The average follow-up period was 19 (1-38) days. The duration of hospitalization was 17 (1-38)days, and the duration of hospitalization in intensive care was 10 (0-30) days. All patients received hydroxychloroquine and favipiravir treatment during their follow-up. In addition, IVIG treatment was given to all patients. While 35 patients (43.2%) received tocilizumab treatment, 15 patients (18.5%) received conventional plasma and 33 patients (40.7%) received pulse steroid treatment. 61.7% of the patients in the first 24 h of their admission to intensive care, and 64.2% of the patients in the first 48 h of their admission to intensive care received IVIG treatment. The demographic, laboratory, and clinical characteristics of the patients have been summarized in Table 1. There was no statistically significant difference between the patients who died during their follow-up and the patients who survived in terms of age, gender, tocilizumab treatment, conventional plasma treatment, and the number of days of hospitalization in the service. We observed significant differences in terms of intubated patient ratio, pulse steroid therapy, hospitalization white blood cell count, hospitalization platelet count, lymphocyte percentage before IVIG treatment, neutrophil count before IVIG treatment, hospitalization C-reactive protein (CRP) values, CRP levels before IVIG treatment, urea values before IVIG treatment, hospitalization lactate dehydrogenase (LDH) levels,

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

hospitalization systemic inflammatory index (SII) levels, SII levels before IVIG treatment, and NLR (Neutrophil Lymphocyte Ratio) levels before IVIG treatment. The comparison of demographic, laboratory, and clinical characteristics of the patients who died and survived has been summarized in Table 1. The univariate analysis found that the number of days of hospitalization in service, being intubated, number of IVIG treatment days, and the urea value before IVIG treatment were independent risk factors for mortality (p:0.043, p:0.001, p:0.074, p:0.004, respectively) (Table 2). As a result of multivariate analysis, being intubated and urea value before IVIG treatment were found to be independent risk factors for mortality (p:0.001 and p:0.009, respectively) (Table 3). It was found that for 60 mg/dL level of urea value before IVIG treatment, the sensitivity value for mortality in COVID-19 patients receiving IVIG treatment was 46.2%, and the specificity was 35.5% (p:0.029) (Table 4) (Figure 1). 4. Discussion The SARS-CoV-2 virus has caused one of the most severe pandemics in human history and has put a lot of pressure, particularly on healthcare systems, since March 2020, when it was declared as a pandemic by WHO. The SARS-CoV-2 virus has caused the deaths of approximately 3 million people in nearly one year since its outbreak (2, 11). At present, there is no globally accepted treatment scheme for treating patients hospitalized for COVID-19. Therefore, it is crucial to determine the prognostic factors in vulnerable patient groups and to develop treatment modalities specific to patient groups according to these factors to reduce mortality and morbidity. In line with this opinion, this study found that being intubated and urea values before IVIG treatment are

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

independent risk factors for COVID-19-related mortality in patients hospitalized for COVID-19 and given IVIG treatment. It has been reported that 7% of COVID-19 patients develop acute renal failure (12, 13). In addition, renal failure has been reported to increase COVID-19-related hospital deaths in mortality studies (14-19). Cheng et al. (15) showed an increase in blood urea nitrogen increased mortality 3.97 times in COVID-19 patients. Another study reported that hospitalization blood urea nitrogen (BUN) and D-dimer levels were associated with mortality, and BUN values of ≥4.6 mmol/L included a high risk for hospital deaths (14). In another study, 6.29% of COVID-19 patients showed an increase in BUN, and increased basal BUN and creatinine values were reported to cause high mortality (17). Ng et al. (18) reported that being intubated and BUN values are risks for hospital mortality in patients with end-stage renal disease and COVID-19. Although the increase in BUN after SARS-CoV-2 is frequent, the reason for this increase is not clear. Renal epithelial cells contain angiotensin-converting enzyme 2 (ACE2) receptors that are 100 times more intense than respiratory epithelial cells; SARS-CoV-2 is internalized to renal cells and may cause renal function loss with cytopathic effect (15, 20). It has been suggested that this may increase the absorption of BUN from the renal tubules by activating the renin-angiotensin-aldosterone system (20). Although IVIG treatment is often used as one of the last treatment options in patients who do not respond to other treatments, IVIG treatment itself may be associated with renal damage (13). On the other hand, the increase in BUN levels in COVID-19 patients may be an indicator of kidney dysfunction and an increased inflammatory state. The renal load caused by increased catabolism, hypovolemia-induced renal hypoperfusion, sepsis,

drugs used in the treatment of COVID-19 such as steroid therapy, and rhabdomyolysis

may also cause an increase in BUN. Although creatinine, another indicator of renal damage, was not found to be a predictor of mortality in this study, the fact that BUN is predictive of mortality suggests that BUN increases due to inflammatory conditions rather than a renal-induced reason and that increased inflammatory processes play a role in making BUN a risk factor for mortality. Another situation supporting this hypothesis is that inflammatory markers of the patients who died before IVIG treatment were prominently higher and statistically significant than the alive patients. As the most common cause of mortality in COVID-19 is a respiratory failure caused by cytokine storm, the majority of patients (81.5%) in the present study had to be followed up in the intensive care unit due to deterioration in their clinical condition. IVIG treatment is one of the last options in COVID-19 patients who are unresponsive to other therapies and whose cytokine storms are not controlled. It was thought that these patients face an intense inflammatory process, which causes an increase in BUN. The retrospective design, relatively small study population, lack of evaluation of other renal markers such as proteinuria and hematuria, and lack of knowledge of what happened in the post-follow-up period form the main limitations of this study.

5. Conclusion

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

In conclusion, the study found that urea values before IVIG treatment were a risk factor for mortality in patients who received IVIG treatment for COVID-19. This is important as it indicates that BUN values should be closely monitored in patients given IVIG treatment for COVID-19. It also suggests that when resources are limited and risk stratification is required in COVID-19 patients, BUN values can be helpful.

References

270

271

- 273 1. Liu X, Liu C, Liu G, Luo W, Xia N. COVID-19: Progress in diagnostics,
- therapy and vaccination. Theranostics 2020; 10(17): 7821-35. 2020/07/21. doi:
- 275 10.7150/thno.47987.
- 276 2. Pollard CA, Morran MP, Nestor-Kalinoski AL. The COVID-19 pandemic: a
- 277 global health crisis. Physiol Genomics 2020; 52(11): 549-57. 2020/09/30. doi:
- 278 10.1152/physiolgenomics.00089.2020.
- Ferrer R. [COVID-19 Pandemic: the greatest challenge in the history of critical
- 280 care]. Med Intensiva (Engl Ed) 2020; 44(6): 323-4. 2020/05/08. doi:
- 281 10.1016/j.medin.2020.04.002.
- 4. Asselah T, Durantel D, Pasmant E, Lau G, Schinazi RF. COVID-19: Discovery,
- diagnostics and drug development. Journal of hepatology 2021; 74(1): 168-84.
- 284 2020/10/11. doi: 10.1016/j.jhep.2020.09.031.
- 285 5. Echeverria-Esnal D, Martin-Ontiyuelo C, Navarrete-Rouco ME, De-Antonio
- 286 Cusco M, Ferrandez O, Horcajada JP, et al. Azithromycin in the treatment of COVID-
- 287 19: a review. Expert review of anti-infective therapy 2021; 19(2): 147-63. 2020/08/28.
- 288 doi: 10.1080/14787210.2020.1813024.
- 289 6. Stasi C, Fallani S, Voller F, Silvestri C. Treatment for COVID-19: An overview.
- 290 European journal of pharmacology 2020; 889: 173644. 2020/10/15. doi:
- 291 10.1016/j.ejphar.2020.173644.
- 292 7. Wang MY, Zhao R, Gao LJ, Gao XF, Wang DP, Cao JM. SARS-CoV-2:
- 293 Structure, Biology, and Structure-Based Therapeutics Development. Frontiers in
- 294 cellular and infection microbiology 2020; 10: 587269. 2020/12/17. doi:
- 295 10.3389/fcimb.2020.587269.
- 8. Bakanlığı TCS, Müdürlüğü HSG. COVID-19 rehberi antisitokin-anti inflamatua
- 297 rtedaviler koagulopati yonetimi. 2020, 7 November.
- 9. Mazeraud A, Goncalves B, Aegerter P, Mancusi L, Rieu C, Bozza F, et al. Effect
- 299 of early treatment with polyvalent immunoglobulin on acute respiratory distress
- 300 syndrome associated with SARS-CoV-2 infections (ICAR trial): study protocol for a
- 301 randomized controlled trial. Trials 2021; 22(1): 170. 2021/03/03. doi: 10.1186/s13063-
- 302 021-05118-7.
- 303 10. Xie Y, Cao S, Dong H, Li Q, Chen E, Zhang W, et al. Effect of regular
- intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with
- 305 COVID-19. J Infect 2020; 81(2): 318-56. 2020/04/14. doi: 10.1016/j.jinf.2020.03.044.
- 306 11. Worldometer. COVID-19 CORONAVIRUS PANDEMIC. 2021, March 28.
- 307 12. Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, et al. Acute
- kidney injury in patients hospitalized with COVID-19. Kidney Int 2020; 98(1): 209-18.
- 309 2020/05/18. doi: 10.1016/j.kint.2020.05.006.
- 310 13. Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin:
- adverse effects and safe administration. Clin Rev Allergy Immunol 2005; 29(3): 173-84.
- 312 2006/01/05. doi: 10.1385/CRIAI:29:3:173.

- 313 14. Cheng A, Hu L, Wang Y, Huang L, Zhao L, Zhang C, et al. Diagnostic
- performance of initial blood urea nitrogen combined with D-dimer levels for predicting
- in-hospital mortality in COVID-19 patients. International journal of antimicrobial
- agents 2020; 56(3): 106110. 2020/07/28. doi: 10.1016/j.ijantimicag.2020.106110.
- 317 15. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is
- associated with in-hospital death of patients with COVID-19. Kidney Int 2020; 97(5):
- 319 829-38. 2020/04/06. doi: 10.1016/j.kint.2020.03.005.
- 16. Liu Q, Wang Y, Zhao X, Wang L, Liu F, Wang T, et al. Diagnostic Performance
- of a Blood Urea Nitrogen to Creatinine Ratio-based Nomogram for Predicting In-
- hospital Mortality in COVID-19 Patients. Risk management and healthcare policy 2021;
- 323 14: 117-28. 2021/01/21. doi: 10.2147/rmhp.S278365.
- 17. Liu YM, Xie J, Chen MM, Zhang X, Cheng X, Li H, et al. Kidney Function
- Indicators Predict Adverse Outcomes of COVID-19. Med (New York, NY) 2021; 2(1):
- 38-48.e2. 2020/10/13. doi: 10.1016/j.medj.2020.09.001.
- 18. Ng JH, Hirsch JS, Wanchoo R, Sachdeva M, Sakhiya V, Hong S, et al.
- Outcomes of patients with end-stage kidney disease hospitalized with COVID-19.
- 329 Kidney Int 2020; 98(6): 1530-9. 2020/08/19. doi: 10.1016/j.kint.2020.07.030.
- 330 19. Shao M, Li X, Liu F, Tian T, Luo J, Yang Y. Acute kidney injury is associated
- with severe infection and fatality in patients with COVID-19: A systematic review and
- meta-analysis of 40 studies and 24,527 patients. Pharmacological research 2020; 161:
- 333 105107. 2020/08/03. doi: 10.1016/j.phrs.2020.105107.
- 334 20. Nogueira SAR, Oliveira SCS, Carvalho AFM, Neves JMC, Silva L, Silva Junior
- GBD, et al. Renal changes and acute kidney injury in covid-19: a systematic review.
- 336 Rev Assoc Med Bras (1992) 2020; 66Suppl 2(Suppl 2): 112-7. 2020/09/24. doi:
- 337 10.1590/1806-9282.66.S2.112.

339

340

341

342

343

344

345

346

347

348

Table 1: Baseline demographic, clinical, and laboratory parameters of the study population

Variable	Total (n: 81)	Dead (n:52)	Alive (n: 29)	p
Age	72 (41-94)	73.0 (41-94)	61 (46-78)	0.391
Gender, F, n (%)	27 (33.3)	17 (32.7)	10 (34.5)	0.870
Follow up time, day	19 (1-60)	20 (1-38)	16 (3-60)	0.745
Duration of illness, day	7 (3-10)	7 (3-10)	7 (3-8)	0.846
Day of stay in hospital	16 (1-44)	17 (1-38)	16 (3-44)	0.557
Day of stay in inpatient service	7.90 ±5.98	7.15 ±6.03	9.24 ±5.75	0.133
Day of stay in intensive care	10 (0-31)	9.5 (0-31)	13 (2-21)	0.509
Intensive care, n (%)	66 (81.5)	48 (92.3)	18 (62.1)	0.001
Intubation, n (%)	37 (45.7)	34 (65.2)	3 (10.3)	0.001
Comorbidity	60 (74.1)	40 (76.9)	20 (69.0)	0.433
Treatment properties				
Convalescent plasma, n (%)	15 (18.5)	9 (17.3)	6 (20.7)	0.707
Pulse steroid therapy, n	33 (40.7)	28 (53.8)	5 (17.2)	0.001
(%)				
Tocilizumab treatment, n (%)	35 (43.2)	19 (36.5)	16 (55.2)	0.105
IVIG treatment, at least	68 (84)	42 (80.8)	26 (89.7)	0.296

three days, n (%)				
IVIG treatment, in first	50 (61.7)	30 (57.7)	20 (69.0)	0.317
24 h, n, %				
IVIG treatment, in first	52 (64.2)	32 (61.5)	20 (69.0)	0.504
48 h, n, %				
Duration of IVIG	3 (1-5)	3 (1-5)	3 (2-5)	0.069
treatment, day				
IVIG dose, gr/day	40 (25-50)	40 (25-50)	50 (30-50)	0.832
Hematological paramete	rs			
WBC count, on	7,960 (1,176-	8,185 (1,176-	7,349.31	0.020
hospitalization	27,350)	27,350)	(2,630-20,110)	
WBC count, before IVIG	9,570 (430-	11,955 (430-	8,190 (1,220-	0.008
treatment	27,290)	27,290)	25,920)	
Neutrophil count, on	7,156.94	7,716.58	6,153	0.136
hospitalization,	±4,508.17	±4,459.34	±4,496.95	
Neutrophil percentage,	84.50 (26.10-	85.50 (26.10-	78.10 (50.20-	0.100
on	96.60)	96.60)	94.20)	
hospitalization				
Lymphocyte count, on	770 (300-	690 (300-	780 (600-	0.512
hospitalization	1,777)	1,770)	1,510)	
Lymphocyte percentage,	11.30 (2.20-	9.30 (2.20-0)	12 (3-33.10)	0.081
on hospitalization	33.10)			
Lymphocyte count,	520 (130-	460 (130-	730 (140-	0.294
before IVIG treatment	1,670)	1,490)	1,670)	

Lymphocyte percentage,	4.30 (0.80-	3.35 (0.80-	5.60 (2.60-	0.001
	,	`	`	
before IVIG treatment	46.50)	46.50)	35.70)	
Platelet count, x10 ³ , on	192 (71-442)	204 (71-372)	191 (75-422)	0.030
hospitalization				
Platelet count, x10 ³ ,	244.19 ±112.82	240.92 ±122.01	250.04 ±95.88	0.730
before IVIG treatment				
Eosinophil count, on	0 (0-130)	0 (0-130)	0 (0-80)	0.689
hospitalization				
Eosinophil percentage,	0 (0-1.20)	0 (0-0.90)	0 (0-1.20)	0.994
on				
hospitalization				
Eosinophil count, before	0 (0-180)	0 (0-180)	0 (0-120)	0.077
IVIG treatment				
RDW, on hospitalization	12.40 ±2.58	12.32 ±2.61	12.55 ±2.56	0.706
RDW, before IVIG	11.80 (8.40-	12.05 (9.40-	10.80 (8.40-	0.394
treatment	20.40)	20.40)	17.70)	
Biochemical Parameters				
Fasting blood glucose,	140 (75-480)	154 (84-361)	122 (75-480)	0.034
mg/dL, on				
hospitalization				
Fasting blood glucose,	165 (77- 344)	180 (88-344)	123 (77-263)	0.195
before IVIG treatment	ore IVIG treatment			
Urea, on	42 (15-256)	42.50 (15-256)	41 (17-180)	0.863
hospitalization				

Urea, before IVIG	59 (17-230)	60.50 (33-230)	43 (17-79.10)	0.029
treatment				
Creatine, on	1.03 (0.58-	1.04 (0.58-	1.02 (0.6-2.20)	0.629
hospitalization	6.87)	6.87)		
Creatine, before IVIG	0.8 (0.5-2.60)	0.9 (0.52-2.60)	0.80 (0.50-	0.544
treatment			1.22)	
LDH, on	457 (188-	516 (190-	384 (188-	0.012
hospitalization	4,367)	4,367)	1,015)	
LDH, before IVIG	570.81 ±213.58	597.10 ±201.48	524.59 ±229.67	0.145
treatment				
D-dimer, on	0.90 (0.20-	0.80 (0.20-	0.90 (0.30-	0.775
hospitalization	5.70)	5.70)	2.10)	
D-dimer, before IVIG	4.59 ±7.59	4.93 ±7.98	3.87 ±6.93	0.549
treatment				
Fibrinogen, on	707.47 ±228.52	720.08 ±247.29	685.39 ±193.60	0.525
hospitalization				
Fibrinogen, before IVIG	635.22 ±279.67	636.81 ±278.53	632.81 ±286.64	0.950
treatment				
Ferritin, on	475.10 (43-	550 (43-4,568)	114 (90.2-	0.389
hospitalization	4568)		1,305)	
Ferritin, before IVIG	655 (83-3,345)	699 (83-3,345)	623 (114-	0.613
treatment			1,659)	
IgG, on hospitalization	8.36 ±4.04	9.64 ±2.70	7.08 ±4.87	0.188
IgM, on hospitalization	0.60 ±0.41	0.58 ±0.49	0.62 ±0.33	0.859

IgA, on hospitalization	2.52 (0.37-	2.56 (0.37-	2.42 (0.37-	0.198
	7.62)	7.62)	7.62)	
Inflammatory Markers				
CRP, on hospitalization	91.2 (3-415)	124 (3-415)	53.70 (8.52-	0.015
			317)	
CRP, before IVIG	47.0 (3.10-297)	82.05 (3.10-	20.80 (3.10-	0.012
treatment		297)	197)	
SII, on hospitalization	1834. 97	1953.0	1064 (352.87-	0.016
	(254.19-	(254.19-	12,962.43)	
	12,962.43)	11,059.84)		
SII, before IVIG	4,166.94	5,086.86	3,753.21	0.013
treatment	(657.69-	(657.69-	(1,354.69-	
	22,356.46)	22,356.46)	13,441.37)	
NLR, on hospitalization	9.19 (1.86-	9.28 (1.93-	7.24 (1.86-	0.075
	42.21)	42.21)	30.72)	
NLR, before IVIG	23.21 (2.33-	26.08 (2.33-	16.15 (5.80-	0.001
treatment	126.31)	126.31)	27.66)	

F: Female, IVIG: Intravenous immunoglobulin, WBC: White blood cell, RDW: Red cell distribution wide, MPV: Mean platelet volume, ALT: Alanine aminotransferase, AST: Aspartate Aminotransferase, LDH: Lactate dehydrogenase, Ig: Immunoglobulin, CRP: C-reactive protein, SII: Systemic inflammatory index, NLR: Neutrophil lymphocyte ratio

Table 2: Univariate Cox regression analyses demonstrating the relationship between

baseline characteristics and Sars-CoV-2

359

Univariate Analysis			
HR (95% CI)	P value		
0.951 (0.906 – 0.998)	0.043		
16.370 (4.353-61.565)	0.001		
0.923 (0.316-0.270)	0.884		
0.910 (0.525 – 1.580)	0.738		
1.436 (0.794 – 2.552)	0.236		
1.419 (0.966 – 2.083)	0.074		
1.234 (0.964 – 1.581)	0.096		
1.000 (1.000 – 1.000)	0.418		
1.000 (1.000 – 1.000)	0.946		
1.001 (0.998 – 1.004)	0.405		
0.994 (0.983 – 1.006)	0.307		
1.002 (0.998 – 1.005)	0.299		
1.002 (0.999 – 1.006)	0.192		
1.011 (1.003 – 1.018)	0.004		
1.000 (0.999 – 1.000)	0.722		
1.000 (0.999 – 1.001)	0.695		
1.025 (0.740 – 1.421)	0.880		
1.002 (0.999 – 1.005)	0.111		
1.001 (0.998 – 1.005)	0.364		
	HR (95% CI) 0.951 (0.906 – 0.998) 16.370 (4.353-61.565) 0.923 (0.316-0.270) 0.910 (0.525 – 1.580) 1.436 (0.794 – 2.552) 1.419 (0.966 – 2.083) 1.234 (0.964 – 1.581) 1.000 (1.000 – 1.000) 1.001 (0.998 – 1.004) 0.994 (0.983 – 1.006) 1.002 (0.998 – 1.005) 1.002 (0.999 – 1.006) 1.000 (0.999 – 1.000) 1.000 (0.999 – 1.001) 1.025 (0.740 – 1.421) 1.002 (0.999 – 1.005)		

SII, on hospitalization	1.000 (1.000 – 1.000)	0.746
SII, before IVIG treatment	1.000 (1.000 – 1.000)	0.314
NLR, on hospitalization	1.002 (0.979 – 1.025)	0.884
NLR, before IVIG treatment	1.004 (0.994 – 1.014)	0.414

Sars-CoV-2: Severe Acute Respiratory Syndrome causing Coronavirus, F: Female,

IVIG: Intravenous immunoglobulin, WBC: White blood cell, RDW: Red cell

distribution wide, MPV: Mean platelet volume, ALT: Alanine aminotransferase, AST:

Aspartate Aminotransferase, FBG: Fasting blood glucose, LDH: Lactate

dehydrogenase, Ig: Immunoglobulin, CRP: C-reactive protein, SII: Systemic

inflammatory index, NLR: Neutrophil lymphocyte ratio

Table 3: Multivariate Cox regression analyses demonstrating the relationship between baseline characteristics and Sars-CoV-2

Variables	Multivariate Analysis			
	HR (95% CI)	P value		
Intubation	0.389 (0.218 – 0.693)	0.001		
Day of stay in inpatient service	0.968 (0.915 – 1.024)	0.256		
Duration of IVIG treatment, day	0.833 (0.652 – 1.065)	0.145		
Urea, before IVIG treatment	1.009 (1.002 – 1.017)	0.009		

372 Sars-CoV-2: Severe Acute Respiratory Syndrome causing Coronavirus, IVIG:


Intravenous immunoglobulin

Table 4: Sensitivity and specificity of urea level before IVIG treatment

Risk factor	AUC (95%)	Cut-off	p	Sensitivity	Specificity
Urea, before IVIG	0.647	60	0.029	46.2	35.5
treatment	(0.518 - 0.776)				

AUC: Area under the curve, IVIG: Intravenous immunoglobulin

Figure 1: Sensitivity and specificity of urea level before IVIG treatment



Diagonal segments are produced by ties.